Dogan, SerdarOkuyan, Hamza MalikBal, TayibeCabalak, MehmetBegen, Mehmet A.2024-09-182024-09-1820230250-46851303-829Xhttps://doi.org/10.1515/tjb-2022-0265https://search.trdizin.gov.tr/tr/yayin/detay/1252069https://hdl.handle.net/20.500.12483/8205Objectives: Roles of Thrombospondin-1 (TSP-1) and Thrombospondin-2 (TSP-2) in tissue repair and inflammation are well-documented, but the association of their serum expressions with the pathogenesis of COVID-19 remains unclear. We investigate the roles of TSP-1 and TSP-2 in COVID-19. Methods: 106 SARS-CoV-2 infected patients and 23 healthy people were enrolled in our study. COVID-19 patients were divided into two groups as non-severe and severe. TSP-1 and TSP-2 concentrations were measured with an enzyme-linked Immunosorbent Assay, and blood markers were analyzed with routine laboratory techniques. Results: COVID-19 patients had significantly higher TSP-1 and TSP-2 levels than healthy controls. TSP-1 and TSP-2 positively correlated with inflammatory markers, including ESR, CRP, PCT, ferritin, and biochemical parameters such as ALT, AST, BUN, CK, and LDH. In addition, TSP-1 and TSP-2 were negatively correlated with hematological markers such as LYM, EOS, and HGB. Receiver operating characteristic analyses revealed that COVID-19 may be predicted with TSP-1 levels over 189.94 ng/mL and TSP-2 levels higher than 0.70 ng/mL. Conclusions: Our analysis suggests that TSP-1 and TSP-2 expressions at the systemic level may have clinical importance for COVID-19.eninfo:eu-repo/semantics/openAccessbiomarkerCOVID-19inflammationThrombospondin-1Thrombospondin-2Article10.1515/tjb-2022-02652-s2.0-85173871650Q31252069WOS:001019169100001Q4